Skip to main content
CLYM logo

CLYM · Climb Bio, Inc.

Track CLYM — free
$9.27 -0.01 (-0.11%)
Market Cap
$545.09M
Shares
58.74M
Volume · Nov 20 225.31K Avg daily vol (3M) 1.37M

Price & Indicators

 

Key stats

Close
$9.28
Thu 19 Nov
Open
$9.36
Thu 19 Nov
Average volume, 30 days
1.2M
shares a session
Short interest
10.6M
18.1% of shares · 7.8 days to cover
Day range
$8.92$9.65
Open $9.36 Close $9.28
52-week closing range
$1.64$17.84
Close $9.28 48.0% under the high
Short volume, last session
55%
Last earnings
Sep 3, 2026
Latest filing
10-Q · Nov 5
Price history
Aug 2021 to Nov 2026

Up next

Dec 31, 2026 Est · unconfirmed · in 6 wks

Latest documents

2026
Nov 9
Investor event
Cash runway reaches second half of 2028, including pivotal spend

Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.

2 source passages
So right now, our cash runway gets us into the second half of 2028, but that is also inclusive of all the Pivotal startup and CMC spend. So we have completed enrollment in the 600. We're enrolling in the 1,000. Open the document at this passage
Nov 9
Investor event
Clinical programs advance toward phase three

Climb Bio is advancing BUDO toward a phase three PMN study and its APRIL antibody toward phase three IgA nephropathy development, with cash runway into the second half of 2028.

8 source passages
Climb Bio, for those of you who don't know us, we're a public biotech company focused on developing B-cell targeted therapies for INI indications. When we in-licensed BUDO, there was a study that had been started but hadn't been finished by the prior sponsor. PMN is a rare renal disease mediated by autoantibodies. It was a single phase three study. The first asset is a CD19-targeted monoclonal antibody, and then the second asset targets APRIL, which is a circulating cytokine that's an important mediator of B-cell differentiation and maintenance. we want to take it into a cohort of patients with IgA nephropathy. we're excited to advance it to phase three. So right now, our cash runway gets us into the second half of 2028, but that is also inclusive of all the Pivotal startup and CMC spend. Open the document at this passage
Nov 5
Registration statement S-3ASR
Launches automatic shelf for future securities

Climb Bio, Inc. launched an automatic shelf registration allowing future sales of multiple securities, with offering amounts and terms to be determined.

Read from the first part of this long document
3 source passages
CLIMB BIO, INC. This prospectus is part of an automatic shelf registration statement on Form S-3ASR that we filed with the Securities and Exchange Commission, which we refer to as the “SEC,” as a “well-known seasoned issuer,” as defined in Rule 405 under the Securities Act of 1933, as amended (the “Securities Act”), utilizing a “shelf” registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Budoprutug shows dose-dependent B-cell depletion

Budoprutug produced deeper peripheral B-cell depletion at 600 mg, with mean suppression of 98% at Week 4. Climb Bio, Inc. reported $227.6 million in cash and marketable securities on September 30, 2026, funding operations into the second half of 2028.

Net loss $14.57M Diluted EPS -$0.18
Read from the MD&A section
2 source passages
Initial data from the ongoing 600 mg cohort suggest greater drug exposure and deeper peripheral B-cell depletion compared with 200 mg, with mean peripheral CD20+ B-cell suppression at Week 4 of 98% at 600 mg compared with 74% at 200 mg. Cash, cash equivalents, and marketable securities were $227.6 million as of September 30, 2026. Based on our current operating plan, we expect this balance to fund operations into the second half of 2028. Open the document at this passage
Nov 5
Current report 8-K
Trial dosing began; remission data reported

Climb Bio began dosing in the NAVIGATE-2 Phase 2 trial for IgAN. Budoprutug’s 200 mg cohort demonstrated B-cell depletion, PLA2R antibody reductions, and immunologic remission at Week 12.

Financial results, Regulation FD disclosure Read from the first part of this long document
3 source passages
Climb Bio, Inc. Initiated dosing in NAVIGATE-2 Phase 2 trial in IgA nephropathy (IgAN); enrollment ongoing. At Week 12, the 200 mg cohort demonstrated B-cell depletion, reductions in PLA2R antibody levels, and immunologic remission. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$59.31M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$205.42M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+17.7%
Year over year · more shares
Price change (1Y)
+404.3%
Trailing year
Short interest
18.1%
Latest settlement · 7.8 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −14%
below
Price vs 50-day avg −17%
below
RSI (14) 41
neutral
MACD trend Negative
52-week position 47%
mid-range
Momentum
relative strength
Weak
1-month return −12%
trailing
6-month return −21%
trailing
YTD return +132%
this year
Relative strength −16%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.07% of shares out · ▲ +8.5% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
128 holders — near 3-yr high, broad support
Squeeze score 66
elevated · 0–100
Fundamentals
Strong
EPS growth +42%
Y/Y
Free cash flow $-54.5M
Balance sheet $35.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −51%
past year
ATR 9.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−14% Bearish
Price vs 50-day avg
−17% Bearish
RSI (14)
41 Neutral
MACD trend
Negative Bearish
52-week position
47% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $11 › 200d $11 — 50d above 200d
Institutional flow Accumulating
+19% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
18.07% of shares out · ▲ +8.5% MoM · 7.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
128 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $9 · 47% Range high $18
vs 200-day avg -14% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Complete platelet response 33% Phase 1b Cohort 1 (6 participants) —
Durable platelet response 67% Phase 1b Cohort 1 (6 participants) —
Free APRIL suppression sustained through 12 weeks 90% 12 weeks following a single SC dose of ≥480 mg —
Fully diluted shares outstanding 81.3M As of Oct 30, 2026 —
Gd-IgA1 reduction at 12 weeks 70% 12 weeks following a single 800 mg dose —
Half-life 33 Phase 1 healthy volunteers (CLYM116) —
IgA reduction 60% Week 12 after a single 800 mg dose —
Mean B-cell depletion 90% Week 4 —
Mean B-cell reduction 84% Week 12 (100 mg cohort) —
Mean increase in platelet count from baseline 111K Week 24 —
Participants enrolled in budoprutug SLE Phase 1b trial 17 As of the October 7, 2026 data cutoff —
Participants in ITP safety analysis population 15 Initial Phase 1b data cut —
Participants who received CLYM116 67 Pooled Australia and China Phase 1 studies —
Participants with any TEAE 12 SLE Phase 1b (18 participants dosed) —
Response among participants with prior rituximab 75% Phase 1b Cohort 1 (4 participants with prior rituximab) —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CLYM
Climb Bio, Inc.
this stock
$545.09M +132.0% — — 18.1%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
128
% held
110.9%
Net QoQ
+8.8M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
130
View
Short & Settlement
Short Interest Rising
Shares short
10.6M
Days to cover
7.8d
Change
+827.1K sh
View
Short Volume
Short vol %
55%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
79.3K
Value
$819.1K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
33.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-59.9M
EPS diluted
$-0.88
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 9, 2026
This year
36

Climb Bio said its cash runway reaches into the second half of 2028, inclusive of all pivotal startup and CMC spend, as it moves toward pivotal studies. For its BUDO program, enrollment in the 600 dose is complete and the 1,000 dose is enrolling.

View
Proposed Sales
Value
$1.5M
Shares
100.0K
Filed
Sep 15, 2026
View
Exempt Offerings
Offering
$110.1M
Filed
May 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 9, 2026
View
Investor Relations
Latest news
Climb Bio Reports Third Quarter 2…
Published
Nov 5, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
CLYM -14.6% -12.0% -21.4% -9.5% +132.0%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -9.2% -5.7% -15.7% -4.2% +127.0%
Key facts CIK 1768446 CUSIP 28658R106 13F (30d) 131 filings 123 filers Visit website Investor relations